Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.84 +1.19 (+10.21%)
Streaming Delayed Price Updated: 3:03 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗
Via The Motley Fool
News headline image
NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information
From Robbins LLP
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
How Is The Market Feeling About Intellia Therapeutics? ↗
 
Via Benzinga
News headline image
13 Analysts Have This To Say About Intellia Therapeutics ↗
 
Via Benzinga
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Peering Into Intellia Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into Intellia Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
9 Analysts Have This To Say About Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA
From Robbins LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: Investors With Large Losses in Intellia Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens ↗
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects. 
Via Stocktwits
News headline image
This RingCentral Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies ↗
Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI. 
Via Benzinga
Topics Government
News headline image
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce ↗
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
News headline image
Why Is Intellia Therapeutics Stock Trading Lower On Friday? ↗
Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership changes, and prepares for commercialization. 
Via Benzinga
News headline image
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? ↗
Via The Motley Fool
News headline image
From GLD To TSLA: Unlocking Today’s Best Trading Opportunities ↗
The week kicks off amidst significant market movements shaped by geopolitical and policy developments. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.